Introduction
The natural recognition and elimination of cancers by the adaptive arm of the immune system often fails and approaches to stimulate this adaptive antitumor immunity can be severely limited by tumor escape mechanisms. [1] [2] [3] One promising approach conceived almost a decade ago was the genetic modification of T cells, resulting in engraftment with integral membrane single-chain Fv (scFv) chimeric signaling receptors, reactive with tumor-associated antigens. 4 ,5 Such T cells have been shown to mediate tumor antigenspecific inhibition of tumor growth in vitro and in vivo, in a major histocompatability complex (MHC) class I-independent manner. 6, 7 Our recent study compared scFv-Fc⑀RI-␥ and T-cell receptor zeta (TCR-) receptors reactive with carcinoembryonic antigen (CEA) and showed the TCR-molecule to be a superior signaling moiety in CD8 ϩ T cells. 7 Since T cells require 2 distinct signals for optimal activation, 8 the engagement of the TCR by peptide in the context of MHC, and a secondary signal provided by costimulatory or accessory molecules, then engineered T cells receiving only one signal after ligation of the tumor antigen might be predicted to be incompletely activated. Indeed, in one study, the ligation of an scFv-chimeric receptor alone was shown to be insufficient to activate naive T cells, and rather a state of T-cell unresponsiveness (anergy) was induced. 9 CD28 provides possibly the most potent comitogenic signal, functioning in synergy with the TCR, as a general amplifier of early TCR signal transduction and modulating the signaling environment around the site of TCR engagement. 10, 11 Costimulation of T cells via CD28 following ligation with tumor cell-surface CD80 and CD86 molecules or bispecific antibody (Ab)-mediated crosslinking to tumor-associated antigen (TAA) has been demonstrated to greatly stimulate subsequent tumor rejection and T-cell memory in vivo. 12, 13 Chimeric receptors incorporating CD28 have been shown to mediate enhanced T-cell activation in vitro. [14] [15] [16] [17] [18] [19] Given that many tumor cells do not express costimulatory ligands, 20 it was not clear whether this approach was sufficient to endow primary T lymphocytes with antitumor efficacy in vivo. Despite their promise, T lymphocytes engineered with scFv chimeras have had limited efficacy against established disease in mouse tumor models. 7 Importantly, we now demonstrate that providing antigen-specific costimulation to gene-modified primary mouse T cells using CD28-containing scFv chimeric receptors can effectively eliminate established tumors using interferon gamma (IFN-␥) and perforin-dependent pathways.
Materials and methods

Cell culture
The human colorectal carcinoma cell lines COLO 205 and Lovo, mouse (C57BL/6 (B6)) colon adenocarcinoma MC-38 and its erbB2 transfectant MC-38-erbB2, the human breast carcinoma cell line MDA-MB-435 (a kind gift from Dr Robin Anderson, Peter MacCallum Cancer Institute, Melbourne, Australia), and the B6 sarcoma cell line 24JK (kindly provided by Dr Patrick Hwu, National Institutes of Health, Bethesda, MD) were maintained in RPMI 1640 or Dulbecco modified Eagle medium (DMEM) at 37°C and 5% CO 2 supplemented with the following additives: 10% (vol/vol) fetal calf serum (FCS), 2 mM glutamine, 100 U/mL penicillin, and 100 g/mL streptomycin (Life Technologies, Grand Island, NY). All tumor cell lines did not express the CD80 and CD86 costimulatory ligands. The retroviral packaging cell lines, GPϩE86 and PA317, and the fibroblast cell line NIH 3T3 were cultured in DMEM with additives. GPϩE86 cells transduced with recombinant retroviral DNA were maintained in DMEM supplemented with 0.5 mg/mL G418 (Life Technologies). Transduced T cells were cultured in DMEM containing 100 U/mL human recombinant interleukin 2 (rIL-2) (kindly provided by Chiron, Emeryville, CA).
Mice
Inbred BALB/c and BALB/c scid/scid (scid) mice were purchased from The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia. BALB/c perforin (pfp)-deficient (BALB/c pfp Ϫ/Ϫ ) and BALB/c IFN-␥-deficient (BALB/c IFN-␥ Ϫ/Ϫ ) mice were bred at the Peter MacCallum Cancer Institute. Mice of 6 to 12 weeks of age were used in all experiments that were performed according to animal experimental ethics committee guidelines.
Chimeric receptor gene construction
A 767-bp fragment of DNA coding for scFv of anti-erbB2 (a kind gift from Dr Winfried Wels, Institute of Experimental Cancer Research, Germany) 21 and a marker epitope from c-myc was amplified by polymerase chain reaction from the pSW50-5 vector and subcloned into XbaI/BstEII-digested pRSVscFv␥R (a kind gift from Zelig Eshhar, Weizmann Institute, Rehovot, Israel). The chimeric gene constructs were composed of the scFv-antierbB2 monoclonal antibody (mAb), a membrane proximal hinge region of human CD8, and the transmembrane and cytoplasmic regions of the human TCR-chain (scFv-anti-erbB2-) or the transmembrane and cytoplasmic regions of the mouse CD28 signaling chain fused to the cytoplasmic region of TCR-(scFv-anti-erbB2-CD28-) ( Figure 1A ). For detection purposes each receptor contained a c-myc tag epitope at the C-terminus of the V L region. The scFv-anti-erbB2 chimeric receptors were digested with SnaB1/ XhoI and subcloned into the HpaI/XhoI restriction sites of the retroviral vector, pLXSN (a kind gift from Dusty Miller, Fred Hutchinson Cancer Research Centre, Seattle, WA) containing the long terminal repeat and a neomycin resistance gene under the control of an SV40 promoter.
Retroviral gene transfer of mouse spleen T lymphocytes
Stable GPϩE86 ecotropic packaging cell lines expressing the scFv-antierbB2-or scFv-anti-erbB2-CD28-receptors were isolated as described previously. 6, 7 GPϩE86 clones producing approximately 10 7 cfu/mL were used for transduction of mouse spleen T lymphocytes. Spleen cells from mice were initially depleted of red blood cells (RBCs) by hypotonic lysis with NH 4 Cl and enriched by passing through a nylon wool syringe as described previously. 7 Enriched T lymphocytes (10 7 ) were then cocultivated for 72 hours with 5 ϫ 10 5 viral-producing packaging cells in DMEM supplemented with 4 g/mL polybrene, 5 g/mL phytohemaglutinin (PHA) (Sigma, St Louis, MO), and 100 U/mL rIL-2. Following cocultivation, T cells were separated from adherent packaging cells, washed with DMEM, and cultured in DMEM supplemented with 100 U/mL rIL-2. T cells were subsequently analyzed for transduction efficiency by flow cytometry and used for in vitro and in vivo experiments. Consistent with previous observations, 6 the majority of T cells selected by the transduction procedure were CD8 ϩ (Ͼ 85% TCR␤ ϩ CD8 ϩ , Յ 6% TCR␤ ϩ CD4 ϩ ) (data not shown).
In some experiments, transduced T cells were treated with anti-mouse CD4 Ab-conjugated immunomagnetic beads (GK1.5, Miltenvi Biotec, Bergisch Gladbach, Germany). CD4 ϩ T cells were depleted using a MAC separator according to the supplier's specifications. Depletion (6% to 0% CD4 ϩ ) was verified by flow cytometry.
Flow cytometry
Detection of cell-surface chimeric receptor expression on mouse T lymphocytes was achieved by indirect immunofluorescence with a c-myc tag Ab purified from supernatants of mouse 9E10 cells, 22 followed by staining with a phycoerythrin (PE)-labeled anti-mouse Ig mAb (Beckon Dickinson, San Jose, CA). Background fluorescence was assessed using a purified IgG1 isotope Ab (3S193; Ludwig Institute for Cancer Research, Melbourne, Australia). Cell-surface phenotyping of transduced cells was determined by direct staining with Quantum-Red-labeled anti-TCR␣␤ (clone H57-597; PharMingen, San Diego, CA); fluorescein isothiocyanate (FITC) anti-CD4 (RM4-5; PharMingen); and Quantum-Red-labeled anti-CD8 (R-3762; Sigma) mAbs as previously described. 6 Cell-surface phenotyping of tumor cell lines was determined by indirect immunofluorescence with anti-human erbB2 (9G6.10, Neomarkers, Fremont, CA), anti-mouse or anti-human CD80 (mouse, 1G10; human, BB1; Sigma), and CD86 (mouse, GL1; human, 2331[FUN-1]; Sigma) mAbs, followed by staining with a fluorophore-labeled anti-Ig mAb.
Antigen-specific binding, cytotoxicity, and cytokine secretion
The binding capacity of gene-modified mouse T lymphocytes was determined in a rosetting assay as described. 7 The cytolytic capacity of transduced T cells was determined in a 6-hour 51 Cr-release assay. Mouse IFN-␥, IL-2, granulocyte macrophage-colony-stimulating factor (GM-CSF), tumor necrosis factor alpha (TNF␣), IL-4, and IL-10 secretion by scFv-modified mouse T lymphocytes after erbB2 antigen ligation was detected by enzyme-linked immunosorbent assay (ELISA). Transduced T cells (10 6 ) (transduced with LXSN plus scFv-anti-erbB2-, scFv-anti-erbB2-CD28-, or mock-transduced T cells) were cultured with 10 6 erbB2 ϩ (Lovo, COLO 205, MDA-MB-435 or MC-38-erbB2) or erbB2 Ϫ (24JK or MC-38) tumor cells in 12-well plates for 20 hours. No exogenous IL-2 was added. Cytokine production through stimulation of endogenous CD3 and CD28 receptors was assessed for each T-effector cell population using soluble CD3 (1 g/mL) (145.2C11; PharMingen) and CD28 (1 g/mL) (37.51; PharMingen) mAbs. Following incubation, supernatants were harvested and the level of cytokine production was measured by ELISA (PharMingen) according to the supplier's specifications.
Proliferation assays
Proliferation assays were performed in 96-well U-bottom plates. The scFv-modified mouse T lymphocytes (10 5 
Adoptive transfer models
The antitumor response of transferred T cells was assessed against 2 different erbB2 ϩ tumor cell lines following subcutaneous inoculation. First, 10 6 mouse 24JK sarcoma cells and/or 5 ϫ 10 6 human COLO 205 colon carcinoma cells were injected subcutaneously into opposite flanks of groups of 5 to 10 scid mice. Spleen T lymphocytes from BALB/c mice (transduced with LXSN plus scFv-anti-erbB2-, scFv-anti-erbB2-CD28-, or mocktransduced T cells) were injected intravenously into groups of 10 scid mice at 6 hours (day 0, 5 ϫ 10 6 ) and 24 hours (day 1, 5 ϫ 10 6 ), on day 3 (10 7 ), or used for titration experiments at day 1 (10 5 , 10 6 , or 10 7 ) after tumor inoculation. In addition, adoptive transfer of scFv-transduced spleen T lymphocytes (5 ϫ 10 6 , day 0 and day 1) from BALB/c pfp Ϫ/Ϫ , BALB/c IFN-␥ Ϫ/Ϫ , or BALB/c pfp Ϫ/Ϫ IFN-␥ Ϫ/Ϫ mice were used to evaluate involvement of pfp and IFN-␥. In the second model, 5 ϫ 10 6 MC-38 and/or MC-38-erbB2 tumor cells were injected subcutaneously into opposite flanks of groups of 5 to 10 scid mice. Spleen T lymphocytes from BALB/c mice (transduced with LXSN plus scFv anti-erbB2-, scFv-anti-erbB2-CD28-, or mock-transduced T cells) were injected intravenously into groups of 10 scid mice at 6 hours (day 0, 5 ϫ 10 6 ) and 24 hours (day 1, 5 ϫ 10 6 ) or on day 3 (10 7 ) after tumor inoculation. Subsequent tumor growth was monitored daily and measured by a caliper square along the perpendicular axes of the tumors. The data were recorded as the mean tumor size (mm 2 , product of the 2 perpendicular diameters) Ϯ SEM.
Experimental pulmonary metastasis model
Scid mice were injected intravenously with 5 ϫ 10 6 human MDA-MB-435 breast carcinoma cells to establish pulmonary metastases. Spleen T lymphocytes (10 7 ) from BALB/c mice (transduced with LXSN plus scFv-anti-erbB2-, -CD28-, or mock-transduced T cells) were injected intravenously into groups of 10 mice at day 1, 5, or 10 after tumor inoculation. In addition, adoptive transfer of scFv-transduced spleen T lymphocytes (10 7 , day 1) from BALB/c pfp Ϫ/Ϫ , BALB/c IFN-␥ Ϫ/Ϫ , or BALB/c pfp Ϫ/Ϫ IFN-␥ Ϫ/Ϫ mice were used to evaluate involvement of pfp and IFN-␥. Mice were monitored daily for tumor growth, indicated by respiratory distress and loss of body condition. There were 3 parameters of tumor growth, determined as follows: (1) in survival experiments, mice that were morbid were killed and the day of death recorded; (2) some groups of mice were killed at day 10 or 18 (when those not receiving T cells were morbid) and whole lung weight (g) was recorded; or (3) some groups of mice were killed at day 10 or 18 and harvested lungs were fixed in 10% formalin, embedded, sectioned and stained with hematoxylin and eosin (H&E) for histologic examination.
Results
Expression of the chimeric scFv-anti-erbB2-and scFv-anti-erbB2-CD28-receptors in primary mouse T lymphocytes
Previous in vitro studies have demonstrated that CD28-containing chimeras can function in human T-cell lines 23 and peripheral blood lymphocytes (PBLs). 14, 16 The coexpression of both scFv-CD28 and scFv-chimeras in Jurkat T cells (with specificities for different antigens) produced maximal levels of IL-2 in response to specific antigens compared with stimulation via either receptor alone. 24 To avoid having to coexpress 2 receptors in T cells, we created a series of scFv (V H and V L ) anti-erbB2 chimeric receptors containing the intracellular domains of CD28 with Fc⑀RI-␥ or TCR-in series. Initially, chimeras were chosen following successful transient transfection in COS-7 cells and these were then stably expressed in Jurkat T cells. Jurkat T cells transduced with chimeras containing the transmembrane and cytoplasmic domains of CD28 fused to the TCR-signaling moiety ( Figure 1A ) produced more IL-2 than Jurkat T cells equivalently expressing the scFv-chimera (data not shown). These data were very encouraging; however, the effectiveness of this type of chimeric receptor needed to be tested in primary T lymphocytes, in vivo. Both receptor gene constructs were subcloned into the retroviral vector pLXSN and high titer virusproducing GPϩE86 clones were used to transduce enriched naive T lymphocytes from BALB/c mouse spleens as previously described. 6 High and equivalent levels of expression of the scFv-antierbB2-and -CD28/ chimeric receptors were reproducibly detected on T cells ( Figure 1B ; n ϭ 5).
Antigen-specific, MHC-independent lysis, enhanced cytokine production, and T-cell proliferation
We next sought to compare the activity of each cytoplasmic domain in stimulating T-cell function against erbB2 ϩ CD80 Ϫ CD86 Ϫ tumor target cells. The cytolytic capacities of T cells expressing either the scFv-anti-erbB2-receptors (T-scFv-cells) or scFv-anti-erbB2-CD28-receptors (T-scFv-CD28-cells) were evaluated in standard 6-hour 51 Cr release assays. T cells expressing either receptor were engrafted with the equivalent ability to specifically conjugate to (binding assays, data not shown) and lyse the erbB2 ϩ human COLO 205 colon carcinoma, MDA-MB-435 mammary carcinoma, and mouse MC-38-erbB2 colon adenocarcinoma cell lines ( Figure  2A ). Equivalent levels of cytolysis were also mediated by both transduced T-effector cell populations after 16 hours (data not shown). Lysis of the erbB2 antigen-negative 24JK mouse sarcoma or MC-38 cell lines was not detected, demonstrating the antigenspecificity of cytolysis (Figure 2A) . Overall, the data indicated that the scFv-CD28-chimera was functional, but that cytolytic function was neither enhanced nor diminished by fusing CD28 and cytoplasmic domains.
One of the major consequences of CD28-mediated signaling is the increased production of T-cell cytokines. 25 We therefore compared the capacity of T-scFv-cells and T-scFv-CD28-cells to produce Tc1 (IFN-␥, GM-CSF, IL-2, TNF-␣) or Tc2 (IL-4 and IL-10) cytokines after specific ligation of erbB2 ϩ cell lines ( Figure  2B ). T-scFv-CD28-cells secreted more than 20-fold higher levels of IFN-␥ and GM-CSF than T-scFv-cells, in an erbB2 antigenspecific manner. The induction of these cytokines was at least equivalent to that observed in the same T cells incubated with anti-CD3/anti-CD28 mAbs ( Figure 2B ). The level of IFN-␥ produced by the T-scFv-CD28-cells was not affected by the depletion of CD4 ϩ T cells from the transduced effector population (T-scFv-CD28-cells versus COLO 205-CD4 ϩ ϩ CD8 ϩ T cells, 5991 pg/mL Ϯ 53 pg/mL; CD4 depleted, 5283 pg/mL Ϯ 186 pg/mL). Similar results were observed against other erbB2 ϩ tumor cell lines. Induction of low levels of IL-2 secretion was also detected from T cells transduced with the scFv-CD28-chimera or following anti-CD3/anti-CD28 mAb stimulation (data not shown). Antigen or anti-CD3/anti-CD28 mAb stimulation of the genemodified CD8 ϩ T cells did not result in the secretion of detectable TNF-␣, IL-4, or IL-10 (data not shown). It is important to note, however, that antigen-specific ligation of the scFv-CD28-chimera, when expressed in other T-cell subsets (eg, CD4 ϩ T cells) or effector cells (eg, NK cells) could potentially stimulate the enhanced production of different Tc1 and Tc2 cytokines. Mocktransduced T cells secreted less than 50 pg/mL Tc1 or Tc2 cytokines after ligation of the erbB2 ϩ cell lines. Another functional downstream effect of CD28 costimulation is enhanced proliferation. 26 We compared the proliferative capacity of T-scFv-cells and T-scFv-CD28-cells by [ 3 H]-thymidine incorporation after specific ligation with irradiated erbB2 ϩ tumor targets for 72 hours ( Figure  2C) . Ligation of the scFv-CD28-chimera induced even greater CD8 ϩ T cell (Ͻ 1% CD4 ϩ ) proliferation compared with antibodymediated stimulation of endogenous CD3 and CD28 receptors expressed on the same T cells ( Figure 2C ). T-scFv-CD28-cells had more than 2-fold enhanced proliferative response compared with T-scFv-cells at all T-cell concentrations examined ( Figure  2C ). After 6 days of culture, the proliferative potential of the transduced T cells significantly decreased; however, T-scFv-CD28-cells still retained enhanced proliferative capacity compared with T-scFv-cells (data not shown). Taken together, these data demonstrated that the scFv-CD28-chimeric receptor was more effective at triggering cytokine production and T-cell proliferation compared with the scFv-receptor, suggesting the CD28 component of the chimera was genuinely costimulatory in T cells.
Inhibition of colon carcinoma by scFv-CD28--transduced T cells
The capacity of the scFv-and scFv-anti-erbB2-CD28-chimeric receptors to stimulate optimal T-cell antitumor function was evaluated in adoptive transfer assays using tumor-bearing scid mice. Transduced T-scFv-or T-scFv-CD28-cells were adoptively transferred intravenously into scid mice 6 hours and 1 day after the subcutaneous inoculation of these mice with erbB2 ϩ COLO 205 or MC-38 tumor in the right flank and erbB2 -24JK or MC-38 tumor, respectively, in the left flank. Both transduced T-cell populations were capable of mediating a significant antigenspecific antitumor response against the erbB2 ϩ tumors, but not the erbB2 Ϫ tumors ( Figure 3A) . Importantly, T-scFv-CD28-cells demonstrated complete eradication of 7 of 10 COLO 205 tumors ( Figure 3A ) and 8 of 10 MC-38-erbB2 tumors ( Figure 3A) . Given the effectiveness of early treatment of the human and mouse colon adenocarcinomas with T-scFv-CD28-cells, we next compared the antitumor efficacy of one dose of T cells (10 7 cells) against 3-day established COLO 205 tumors (mean size ϳ 8 mm 2 ). Although no complete tumor eradications were observed, statistically greater inhibition of growth of erbB2 ϩ COLO 205 tumors was observed in mice injected with T-scFv-CD28-cells compared with T-scFvcells ( Figure 3B ). Similar data were obtained with T-cell transfers into scid mice with established MC-38-erbB2 tumors (data not shown). To further compare the potency of T-scFv-CD28--mediated response(s) in vivo we assessed the antitumor efficacy of different doses of T-scFv-cells or T-scFv-CD28-cells (10 7 , 10 6 , or 10 5 ) injected into groups of 10 scid mice at day 1 after COLO 205 tumor inoculation ( Figure 3C ). Impressively, T-scFv-CD28-cells were at least 10-fold more potent than T-scFv-cells in inhibiting tumor growth (P Ͻ .01), and 10 6 T-scFv-CD28-cells eradicated tumors in 5 of 10 mice compared with 2 of 10 mice injected with 10 7 T-scFv-cells ( Figure 3C ). The greater antitumor capacity of T-scFv-CD28-cells was clearly evident from 3 independent experiments where collectively a total of 30 mice were inoculated with either 10 7 T-scFv-CD28-cells or 10 7 T-scFvcells (T-scFv-CD28-cells: 25 tumor-free versus T-scFv-cells: 8 tumor-free, P Ͻ .0001). 
Perforin and IFN-␥ are critical for the antitumor activity of T-scFv-CD28-cells
To determine why T-scFv-CD28-cells were so effective in vivo, we next sought to evaluate the relative importance of their cytotoxicity and IFN-␥ secretion in controlling tumor growth. T cells from BALB/c wild-type (WT), IFN-␥ Ϫ/Ϫ , perforin (pfp) Ϫ/Ϫ , and pfp Ϫ/Ϫ IFN-␥ Ϫ/Ϫ mice were transduced with the scFv-CD28-or scFv-chimeric receptors. Importantly, expression of the scFv-CD28-( Figure 4A ) and scFv-(data not shown) chimeras in T cells from gene-targeted mice was equivalent to that detected in WT T cells. Phenotypic characterization of the scFv-CD28--transduced T cells from all mouse strains confirmed that only pfp Ϫ/Ϫ and pfp Ϫ/Ϫ IFN-␥ Ϫ/Ϫ T cells had defective cytolytic activity against the MC-38-erbB2 ϩ tumor cells ( Figure 4B ). Transduced pfp Ϫ/Ϫ T cells retained a similar capacity to produce IFN-␥ as WT T cells, following antibody-mediated stimulation of endogenous CD3 and CD28 receptors (data not shown). The proliferative ability of T cells from all 3 mutant mouse strains, following chimeric receptor ligation by erbB2 antigen or stimulation of endogenous CD3 and CD28 receptors, was observed to be at least equivalent to that of transduced WT T cells ( Figure 4C ). Having established the in vitro functional capacity of transduced T cells from each of the mutant strains of mice, the ability of these T cells to mediate in vivo tumor protection was compared against the antitumor activity of WT T cells. 
IFN-␥-dependent inhibition of established lung metastases by T-scFv-CD28-cells
Considering the ability of the scFv-CD28-chimera to confer to T cells antitumor activity against established subcutaneous tumors, including MDA-MB-435 (data not shown), we next tested efficacy of transduced T cells against established human MDA-MB-435 breast carcinoma metastases in scid mice. Chimera-transduced T cells were adoptively transferred intravenously into scid mice on day 1, 5, or 10 after the intravenous inoculation of MDA-MB-435 tumor cells. The MDA-MB-435 tumor cells effectively lodge in the lung and grow rapidly, killing the mice within 16 to 20 days of inoculation. Adoptive transfer of T-scFv-CD28-cells one day after tumor inoculation rescued 80% of mice (8 of 10), compared with 20% survival of mice receiving T-scFv-cells ( Figure 6A ). The delay of T-cell transfer until day 5 reduced the number of tumor eradications (60% survival) mediated by T-scFv-CD28-cells ( Figure 6B ). T-scFv-cells were partially effective, prolonging survival of 20% of mice beyond that observed for animals receiving mock-transduced T cells or no T-cell treatment; however, all the mice in this group did succumb to tumor ( Figure 6B ). Just as observed in the xenogeneic COLO 205 tumor model, the enhanced IFN-␥ production by T-scFv-CD28-cells was absolutely critical for the superior antitumor activity of these effector cells against It must be noted that few immunotherapies have ever been described that can eliminate established solid tumors or metastases, even in mouse experimental models. Most dramatic was the potency of 10 7 T-scFv-CD28-cells against 10-day established lung metastases, with all the treated mice surviving longer than other treated mice and some surviving indefinitely (2 of 20 were tumor-free for more than 50 days, Figure 6D ). By contrast, T-scFv-cells had no significant antitumor effect against such advanced lung metastases. It should be noted that 10 days after MDA-MB-435 tumor inoculation, the lungs of untreated mice were considerably tumor burdened (whole lung weight, 0.78 Ϯ 0.01 g) ( Figure 7A ). On day 18, 8 days after T-cell transfer, the mean weights of lungs isolated from mice receiving mock-transduced T cells (1.10 Ϯ 0.15 g) or no treatment (1.38 Ϯ 0.05 g) were approximately 6 times larger than those from T-scFv-CD28-cell-treated mice (0.28 Ϯ 0.08 g; *P Ͻ .01, **P Ͻ .001, n ϭ 10) ( Figure 7A ). Lungs isolated from normal scid mice weighed 0.17 Ϯ 0.01 g. Histology (H&E staining) of these lungs at day 18 distinctly demonstrated a large reduction of MDA-MB-435 tumor mass ( Figure 7F ) upon T-scFv-CD28-cell treatment with the maintenance of normal lung structure still evident in many areas of the lung. By comparison, lungs isolated from mice receiving no treatment, 10 days ( Figure 7C ) or 18 days after tumor inoculation ( Figure 7D ), were consumed with tumor cells and had completely lost all normal lung architecture. An equivalent level of tumor burden was also observed in lungs isolated at day 18 from mice receiving mock-transduced T cells ( Figure 7E ). These data graphically demonstrated for the first time the ability of adoptively transferred T cells to reduce established metastatic tumor burden.
Discussion
The transfer of specific chimeric antigen-recognition receptors into T cells offers great potential to target T cells to any tumorassociated antigen of interest. Specifically, redirecting T cells using scFv of antibody-chimeric receptors enables the efficient binding of effector T cells to tumors in a non-MHC-restricted fashion, thus bypassing the MHC/peptide complex loss that is a major escape mechanism for most tumors. 27 Nevertheless, previous scFvchimeric receptor designs that incorporated TCR-or Fc⑀RI-␥ intracellular signaling domains did not account for the need to provide T cells with 2 signals for activation, thus limiting the effectiveness of redirected T cells against many tumors that down-regulate or lose costimulatory ligands such as CD80 and CD86. In this study we have made a significant and practical advance in providing tumor costimulation by demonstrating the greatly enhanced in vivo function of an scFv-anti-erbB2-chimera containing both the CD28 and TCR-signaling moieties fused in a single receptor. We have illustrated that primary mouse T-scFv-CD28-cells produce greatly elevated levels of IFN-␥ and enhanced proliferation upon erbB2 ligation and in so doing evoke a vigorous antitumor response in vivo. Direct comparison with T cells expressing an otherwise identical receptor that lacked the CD28 cytoplasmic domain demonstrated the superior efficacy of the scFv-CD28-chimera in established human tumor and experimental metastasis models in scid mice. We have also obtained similar data using T-scFv-CD28-cells recognizing carcinoembryonic antigen (CEA), demonstrating the general utility of this approach (data not shown). The degree of control of established tumors and metastases lacking CD80/86 expression, by T-scFv-CD28-cells, exceeded that afforded by other approaches using tumor infiltrating lymphocytes (TIL), 28 lymphokine activated killer (LAK) cells, 29 or gene-modified TIL 30 in conjunction with highdose IL-2 administration.
A most striking observation from our studies using T cells from gene-targeted mice was that the superior antitumor efficacy of the scFv-CD28-chimera (compared with the scFv-receptor) in vivo was critically dependent on the antigen-specific secretion of the Tc1 cytokine, IFN-␥. By contrast, pfp was found to be essential for effective tumor rejection mediated by T cells expressing either chimeric receptor. Although a role for pfp in the direct lymphocytemediated cytolysis of tumors has been well documented, 6,31 the most important antitumor activity of IFN-␥ remains unclear. There are a number of studies suggesting that IFN-␥ can mediate its effect on tumors directly or indirectly. [32] [33] [34] Importantly, in our study, the lack of murine T-cell secreted IFN-␥ activity on human tumor cell IFN-␥ receptors excludes a direct mechanism of action of IFN-␥. Possible indirect mechanisms of action include the recruitment and activation of endogenous immune effector cells, 35 the regulation of leukocyte-endothelium interactions, 35, 36 or the antiangiogenic properties of IFN-␥. 26, 37, 38 Although scid mice lack mature T and B cells, the potential indirect mechanisms to be explored (above) require far more extensive study. While we have demonstrated the key need for T-cell IFN-␥ secretion, the elevated secretion of other Tc1 proinflammatory cytokines may also be contributing to the antitumor response mediated by the T-scFv-CD28-cells. 39, 40 Further adoptive transfer and immunohistology studies with redirected T cells from WT and other gene-targeted mice should reveal which effector molecules and host cells contribute to the improved efficacy of T-scFv-CD28-cells. An alternative explanation for the superior antitumor response mediated by these gene-engineered 10 6 ). Mice were injected intravenously with a single dose (10 7 ) of either BALB/c WT T-pLXSN cells or T-scFv-anti-erbB2-CD28-cells on day 10 after tumor inoculation. Normal whole lung weight (g) (no tumor, normal lung, n ϭ 2) or control (not receiving T-cell transfer) whole lung weight from tumor-inoculated mice at day 10 (n ϭ 2) or day 18 (n ϭ 10) were also recorded. Significant differences in lung weight were determined by Mann-Whitney test and denoted (*P Ͻ .01, **P Ͻ .001). T cells in vivo is that costimulation through CD28 can regulate not only cytokine secretion but also T-cell proliferation and survival. 41 We have demonstrated that antigen-specific ligation of the scFv-CD28-chimera resulted in enhanced expansion of the genemodified T cells in vitro. We have not yet evaluated the proliferation and survival of scFv-CD28--engineered and -transferred T cells in tumor-bearing mice; however, another study has indicated that mouse T cells retrovirally engineered with TCR genes can survive up to 80 days after transfer into immunocompromised mice. 42 Importantly, in the context of our study, it should be noted that IFN-␥ normally promotes the death of antigen-activated T cells 43 rather than promoting survival.
Another important observation in our study was the equivalent cytokine secretion triggered by the scFv-CD28-receptor compared with ligating endogenous CD3 and CD28 receptors on primary T cells with reactive mAbs. Therefore, signaling through the CD28 and TCR-motifs of the scFv-chimera, closely aligned in cis, functions at least equivalently for cytokine induction and T-cell proliferation as when the 2 motifs are positioned physiologically in trans. This in itself was an advance on a previous similar study performed in transformed Jurkat T cells. 15 We have not, as yet, investigated the signaling mechanisms by which the scFv antierbB2-CD28-receptor triggers enhanced cytokine secretion or proliferation. The capacities of endogenous CD28 to induce cytokine gene transcription 44, 45 and influence and sustain TCR signaling 10, 46 are well defined. T-cell activation via the scFv-CD28-chimera may also serve to further increase the strength and time of interactions between T cells and tumor cells, thereby enhancing T-cell responsiveness. In the future, it will be interesting to evaluate whether the scFv-CD28-chimera mimics the synergistic signaling activities of endogenous TCR and CD28 or provides alternative signaling pathways.
It is notable that even the most successful recent studies that have redirected T-cell specificity using scFv chimeras 7, 30 or TCR genes 42, 47 have protected against minimal tumor burden. By contrast, we have successfully retrovirally infected the majority of primary mouse T cells and demonstrated significant efficacy of these T-scFv-CD28-cells in vivo when administered distant from established (up to 10 days) and rapidly growing tumors. No loss of antigenic specificity occurred with the scFv approach despite the increased potency (Ͼ 10-fold) of these engineered T cells. Overall this study has demonstrated the practicality of providing T cells with primary and costimulatory signals using a single scFvchimeric receptor that recognizes a tumor antigen. The T-scFv-CD28-cells eliminated tumors in the absence of exogenous IL-2 administration, and given that similarly transduced human T cells produce IL-2 16 this approach may eliminate IL-2 toxicity associated with other adoptive immunotherapies using TILs and LAK cells. 48 Despite encouraging clinical results for cellular immunotherapies using LAK cells and TILs, 48 their general application to all cancers has been hampered by lack of specificity, poor homing capabilities, and difficulty in isolating a sufficient number of these cells. Redirected CTL therapy involving expression of chimeric receptors has several advantages over other immunotherapies due to (1) abundance of naive T cells available for gene transfer, (2) variety of TAA expressed on a broad spectrum of tumors, and (3) MHC-unrestricted reactivity of scFv-chimeric receptors. Although in many instances the MHC/peptide may be a more specific target than a TAA, many tumors readily down-regulate the expression of MHC/peptide complexes. While effective gene-delivery and autoimmunity remain hurdles with redirected CTL approaches, rapid advances in gene transfer technology and humanization of vectors coupled with the encouraging in vivo data presented herein compel further translation of the scFv approach to eventual clinical trials of safety and efficacy. Our ultimate goal of optimizing the signaling capacity of scFv-chimeric receptors has been to significantly enhance the specificity and potency of antitumor T cells. Our demonstration of the efficacy and effector mechanisms provided by a novel scFv-CD28-receptor in vivo represent a significant advance in genetically providing T cells with the specificity and appropriate costimulation to reject tumors.
